A Case of Acquired Factor V Inhibitor Following Nivolumab Administration

Acquired factor V inhibitor (AFVI) is a very rare disease. We presented herein a case of hypopharyngeal cancer in which AFVI developed after nivolumab administration. Blood test findings two weeks after the first dose of nivolumab showed a significant prolongation of prothrombin time (PT) and activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kida, Wataru, Nakaya, Muneo, Ito, Akiko, Kozai, Yasuji, Bingo, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Otolaryngology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884452/
https://www.ncbi.nlm.nih.gov/pubmed/35242461
http://dx.doi.org/10.7759/cureus.21670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884452/
https://www.ncbi.nlm.nih.gov/pubmed/35242461
http://dx.doi.org/10.7759/cureus.21670

Ejemplares similares